Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib
MOH_2019-09-10_006023Phase 3Not yet recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Apr 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Ripretinib arm with Sunitinib comparator arm (2 arms). Primary endpoint: Progression-free survival. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
ripretinibsunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on MOH_2019-09-10_006023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-10_006023.